R&D | October 28, 2025
MilliporeSigma partners with Promega to advance 3-D cell drug discovery technologies
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Lutavit A/D3 1000/200 NXT provides a combination of vitamin A and vitamin D3 in one formulation
This new suite of products demonstrates Nouryon’s leadership in cleaning ingredient solutions
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
Subscribe To Our Newsletter & Stay Updated
